Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» kidney disease
kidney disease
Travere’s Kidney Disease Drug Narrowly Misses Phase III Endpoint, Stock Tanks
Travere’s Kidney Disease Drug Narrowly Misses Phase III Endpoint, Stock Tanks
BioSpace
Travere Therapeutics
kidney disease
sparsentan
Filspari
clinical trials
Flag link:
ProKidney drops $25.5M on North Carolina manufacturing site for cell therapy prospect
ProKidney drops $25.5M on North Carolina manufacturing site for cell therapy prospect
Fierce Pharma
ProKidney
drug manufacturing
North Carolina
kidney disease
Flag link:
Novartis to acquire kidney disease biotech Chinook for up to $3.5B
Novartis to acquire kidney disease biotech Chinook for up to $3.5B
BioPharma Dive
Novartis
Chinook Therapeutics
M&A
kidney disease
Flag link:
HI-Bio's expectations elevated after pair of phase 2 readouts bolster autoimmune ambitions
HI-Bio's expectations elevated after pair of phase 2 readouts bolster autoimmune ambitions
Fierce Biotech
Hi-Bio
Human Immunology Bioscience
kidney disease
felzartamab
Flag link:
Goldfinch Bio falls from the sky after failing to find a path forward for kidney treatments
Goldfinch Bio falls from the sky after failing to find a path forward for kidney treatments
Fierce Biotech
Goldfinch Bio
GFB-887
kidney disease
Flag link:
As Roche prepares to take a kidney disease drug into PhIII, Ionis fleshes out the data
As Roche prepares to take a kidney disease drug into PhIII, Ionis fleshes out the data
Endpoints
Roche
Ionis Pharmaceuticals
IONIS-FB-LRx
kidney disease
Flag link:
Autoimmune drug biotech HI-Bio unveils $120M to root out cellular drivers of disease
Autoimmune drug biotech HI-Bio unveils $120M to root out cellular drivers of disease
MedCity News
Human Immunology Bioscience
autoimmune disease
R&D
MorphoSys
kidney disease
Flag link:
Tricida’s shares plunge as phase 3 fail seals fate of FDA-rejected kidney disease drug
Tricida’s shares plunge as phase 3 fail seals fate of FDA-rejected kidney disease drug
Fierce Biotech
Tricida
clinical trial
kidney disease
Veverimer
Flag link:
FDA’s liver safety request set to delay decision on Travere’s kidney drug
FDA’s liver safety request set to delay decision on Travere’s kidney drug
Fierce Biotech
Travere Therapeutics
kidney disease
REMS
FDA
Flag link:
Regulus reports positive findings from Phase I kidney disease trial
Regulus reports positive findings from Phase I kidney disease trial
Clinical Trials Arena
Regulus
kidney disease
RGLS8429
clinical trials
Flag link:
Where Will Vertex Pharmaceuticals Be in 1 Year?
Where Will Vertex Pharmaceuticals Be in 1 Year?
Motley Fool
Vertex Pharmaceuticals
cystic fibrosis
kidney disease
Flag link:
Novartis' MS drug Gilenya could inspire new chronic kidney disease treatment
Novartis' MS drug Gilenya could inspire new chronic kidney disease treatment
Fierce Biotech
Novartis
Gilenya
kidney disease
chronic kidney disease
Flag link:
Travere fails to convince regulators to consider accelerated approval for a rare kidney disease — again
Travere fails to convince regulators to consider accelerated approval for a rare kidney disease — again
Endpoints
Travere Therapeutics
Martin Shkreli
sparsentan
FDA
kidney disease
Flag link:
Bayer-Ionis' anti-thrombotic med doesn't increase bleeding in phase 2, setting stage for a new type of anticoagulant
Bayer-Ionis' anti-thrombotic med doesn't increase bleeding in phase 2, setting stage for a new type of anticoagulant
Fierce Biotech
Bayer
Ionis Pharmaceuticals
kidney disease
clinical trials
fesomersen
Flag link:
Is the HIF-PHI class of next-generation kidney drugs doomed in the U.S.?
Is the HIF-PHI class of next-generation kidney drugs doomed in the U.S.?
MedCity News
HIF-PHI
kidney disease
FDA
vadadustat
Flag link:
Sanofi walks away from kidney disease therapy, leaving $25M in milestones out of reach for Regulus
Sanofi walks away from kidney disease therapy, leaving $25M in milestones out of reach for Regulus
Fierce Biotech
Sanofi
kidney disease
Regulus
lademirsen
Flag link:
Ionis hands off an antisense drug for kidney disease, giving all rights to Roche
Ionis hands off an antisense drug for kidney disease, giving all rights to Roche
Endpoints
Ionis Pharmaceuticals
Roche
IONIS-FB-LRx
clinical trials
immunoglobin A nephropathy
kidney disease
Flag link:
Medtronic to Spin Renal Business into New Company
Medtronic to Spin Renal Business into New Company
Medical Devices and Diagnostics Industry
Medtech
kidney disease
Medtronic
spinoffs
DaVita
Flag link:
ACC: Bayer’s Kerendia cuts cardio and kidney complications in high-risk patients
ACC: Bayer’s Kerendia cuts cardio and kidney complications in high-risk patients
Fierce Pharma
Bayer
ACC
kidney disease
Kerendia
Flag link:
Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease
Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease
Yahoo/Businesswire
Vertex Pharmaceuticals
kidney disease
VX-147
clinical trials
Flag link:
Pages
1
2
3
4
5
6
next ›
last »